Loading stock data…
$1.70-0.04 (-2.30%)
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.
Cerenome, Inc. in the Healthcare sector is trading at $1.70 with a market capitalization of $20M. Wall Street consensus targets $27.75 (4 analysts), implying a +1532.4% move over the next 12 months. The stock is currently near its 52-week low of $1.49, remaining 68.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$9.06M↓ | -$7.12M↓ | -$5.74M↓ | -$4.48M↓ | -$1.54M |
| Net Income | -$9.01M↓ | -$6.95M↓ | -$5.71M↓ | -$4.42M↓ | $5.15M |
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiothera...